SpyGlass Pharma, Inc. (SGP) Financial Statements
Industry: Surgical & Medical Instruments & Apparatus
In fiscal 2025, SpyGlass Pharma reported revenue of $0. Net income was -$39.9M, or -$17.98 per diluted share. Operating activities generated -$32.7M of cash, leaving -$33.5M of free cash flow. At fiscal year end, SpyGlass Pharma held $115.9M in total assets against $10.2M in total liabilities, including $96.4M of cash and equivalents.
Open the full interactive SpyGlass Pharma financials → Quarterly statements, key ratios, valuation history and price charts.
SpyGlass Pharma Key Stats
| Share Price | $23.92 |
|---|---|
| Market Cap | $799.9M |
| 52-Week Range | $17.56 – $29.68 |
| Shares Outstanding | 33.4 million (basic, 2026 Q2) |
SpyGlass Pharma Income Statement
| FY 2025 | |
|---|---|
| Revenue | $0 |
| Operating Income | -$41.4M |
| Pre-Tax Income | -$39.9M |
| Income Tax | $0 |
| Net Income | -$39.9M |
| Diluted EPS | -$17.98 |
SpyGlass Pharma Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Revenue | $0 | $0 |
| Net Income | -$13.8M | -$19.9M |
| Diluted EPS | -$0.69 | -$0.59 |
SpyGlass Pharma Balance Sheet
| FY 2025 | |
|---|---|
| Cash & Equivalents | $96.4M |
| Current Assets | $108.8M |
| Total Assets | $115.9M |
| Current Liabilities | $8.6M |
| Total Liabilities | $10.2M |
| Shareholders' Equity | -$98.8M |
SpyGlass Pharma Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$32.7M |
| Cash From Investing | -$11.8M |
| Cash From Financing | $124.6M |
| Free Cash Flow | -$33.5M |
Figures from SpyGlass Pharma's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full SpyGlass Pharma financials page for every line item.
SpyGlass Pharma Company Profile
| Ticker | SGP |
|---|---|
| Exchange | Nasdaq |
| Industry | Surgical & Medical Instruments & Apparatus |
| Headquarters | Irvine, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001778922 |
Frequently Asked Questions
What was SpyGlass Pharma's revenue in fiscal 2025?
SpyGlass Pharma (SGP) reported revenue of $0 for fiscal 2025.
What was SpyGlass Pharma's net income in fiscal 2025?
SpyGlass Pharma reported net income of -$39.9M for fiscal 2025.
What was SpyGlass Pharma's earnings per share (EPS) in fiscal 2025?
SpyGlass Pharma's diluted EPS was -$17.98 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did SpyGlass Pharma generate in fiscal 2025?
SpyGlass Pharma generated -$33.5M of free cash flow in fiscal 2025.
What was SpyGlass Pharma's revenue last quarter?
In its most recent reported quarter (2026 Q2), SpyGlass Pharma reported revenue of $0.
How many shares of SpyGlass Pharma are outstanding?
SpyGlass Pharma reported a weighted average of 33.4 million basic shares outstanding in 2026 Q2.
What is SpyGlass Pharma's market cap?
Based on its latest closing price, SpyGlass Pharma (SGP) has a market capitalization of about $799.9M.
When does SpyGlass Pharma's fiscal year end?
SpyGlass Pharma's fiscal year end, as registered with the SEC, is December 31.
Where is SpyGlass Pharma headquartered?
SpyGlass Pharma lists its business address in Irvine, California in its SEC filings.
SpyGlass Pharma Competitors & Similar Companies
See all 109 Surgical & Medical Instruments & Apparatus companies →